Training · Nutrition · Recovery
hCG and enclomiphene: how their mechanisms of action, point of impact on the hormonal axis, effect on spermatogenesis, pharmacokinetics, risks and regulatory status differ. An editorial breakdown.
hCG or enclomiphene: in which clinical situations doctors consider each option, for whom they are unsuitable, which tests are needed before the choice, and why both are banned for athletes.
Tamoxifen and enclomiphene: two estrogen receptor modulators with different chemistry, metabolism, tissue action, indications and risks. An editorial comparison with references.
Tamoxifen or enclomiphene: for whom doctors consider each SERM — gynecomastia, oncology, secondary hypogonadism, fertility — and when both are contraindicated. A practical editorial review.
Raloxifene and clomiphene: SERMs of different generations with different chemical structure, tissue profile, bioavailability and indications — from osteoporosis to ovulation induction. An editorial breakdown.
Raloxifene or clomiphene: for whom each drug is intended — postmenopausal osteoporosis, infertility, male hypogonadism, gynecomastia — and the alternatives doctors consider today.
Letrozole and exemestane: a non-steroidal reversible and a steroidal irreversible aromatase inhibitor. Mechanism, pharmacokinetics, degree of estrogen suppression, effect on bones and lipids — an editorial breakdown.
Letrozole or exemestane: in which clinical situations oncologists and reproductive specialists choose each aromatase inhibitor, for whom they are contraindicated, and why self-prescription by men is dangerous.
Cabergoline and vitamin B6 for elevated prolactin: a dopamine D2 receptor agonist versus a cofactor of dopamine synthesis. Mechanisms, evidence, risks and the limits of expectations — an editorial breakdown.
Cabergoline or vitamin B6 for elevated prolactin: who needs a prescription dopamine agonist, who needs a dietary correction, and who needs no treatment at all. A practical algorithm from the editorial team.
hCG and enclomiphene: how their mechanisms of action, point of impact on the hormonal axis, effect on spermatogenesis, pharmacokinetics, risks and regulatory status differ. An editorial breakdown.
hCG or enclomiphene: in which clinical situations doctors consider each option, for whom they are unsuitable, which tests are needed before the choice, and why both are banned for athletes.
